CompletedNCT02902601
Safety of JNJ-54175446 in Adults With Major Depression
About this title
Read the official source —Medication studyAges 18–64Germany + Netherlands
Understand this study
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- Berlin and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: October 17, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 70
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Germany, Netherlands
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT02902601
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Subjects With Major Depressive Disorder
Get this study by email
Recruitment & locations
CompletedBerlin, Germany · Hamburg, Germany · Schwerin, Germany
1 more locations
- Leiden, Netherlands
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including JNJ-54175446, 600 mg and JNJ-54175446, 150 mg.
Who was this study for?
Listed age limits: 18 years to 64 years.
Want to explore more studies?
Explore studiesRelated studies
Esketamine Added to Standard Care for Depression With Imminent Suicide Risk
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression